MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Dynavax Technologies Corporation Interest Expense 2011-2026 | DVAX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Dynavax Technologies Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 293 K | -152 K | 111 K | 11.2 M | 19.1 M | 17 M | 9.34 M | -486 K | -2.49 M | 572 K | 35 K | -348 K | 2.35 M | 1.96 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.1 M | -2.49 M | 4.17 M |
Quarterly Interest Expense Dynavax Technologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27 K | -596 K | -423 K | - | -152 K | 1.7 M | 101 K | - | 266 K | 1.69 M | 1.69 M | - | 1.68 M | 1.68 M | 1.68 M | - | 1.68 M | 3.11 M | 4.71 M | - | 4.79 M | 4.73 M | 4.73 M | - | 4.78 M | 4.6 M | 2.73 M | - | 2.74 M | 2.69 M | 1.16 M | - | -166 K | -232 K | 20 K | - | -26 K | 48 K | 46 K | - | 62 K | 263 K | 247 K | - | 216 K | 22 K | 62 K | - | 24 K | 27 K | 32 K | - | 589 K | 589 K | 587 K | - | 485 K | 487 K | 490 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.79 M | -596 K | 1.24 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M |  USA |
 |
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | USA |
 |
Nanobiotix S.A.
NBTX
|
-4.68 M | $ 30.34 | -0.82 % | $ 286 B |  France |
 |
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | USA |
 |
I-Mab
IMAB
|
722 K | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
58 K | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | USA |
 |
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | France |
 |
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
14.2 M | $ 95.5 | 3.83 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Aytu BioScience
AYTU
|
-512 K | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
443 K | $ 24.21 | -1.47 % | $ 3.08 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
927 K | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
18.9 M | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
2 M | $ 3.13 | -1.26 % | $ 315 M | USA |
 |
Codiak BioSciences
CDAK
|
2.7 M | - | -55.98 % | $ 2.15 M | USA |
 |
Avid Bioservices
CDMO
|
4.34 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
5.81 M | - | - | $ 1.41 B | USA |
 |
InflaRx N.V.
IFRX
|
2.69 K | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
Immutep Limited
IMMP
|
8.2 K | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-309 K | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
100 K | $ 3.83 | -2.3 % | $ 258 B |  Britain |
 |
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | USA |
 |
Celsion Corporation
CLSN
|
5.03 M | - | -6.63 % | $ 13.9 M | USA |